This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Reviewing the use of the clonoSEQ assay test for minimal residual disease (MRD) detection in blood cancer patients

Ticker(s): ADPT

Who's the expert?

Institution: University of California, Irvine

  • Assistant Clinical Professor at the UCI School of Medicine
  • Hematolgy/Oncology physician who sees over 50 patients with lymphoma and regularly orders the clonoSEQ MRD assay
  • Research interests in lymphoma, Bcl2 family, and apoptosis

 

Interview Questions
Q1.

Please describe your background and practice setting

Added By: ben_admin
Q2.

How many patients with myeloma do you manage monthly?

Added By: ben_admin
Q3.

When are you ordering MRD testing for patients?

Added By: ben_admin
Q4.

How frequently do you order the clonoSEQ assay?

Added By: ben_admin
Q5.

What were your impressions of the clonoSEQ data presented at ASCO 2023?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.